Category: 3. Business

(Bloomberg) — Wall Street traders sent stocks down from all-time highs, with a weak reading on consumer sentiment and an increase in inflation expectations tempering optimism about solid retail sales.

The end of a week that saw investors juggling contradictory signs on the inflation front also brought inconclusive indications about how Americans are feeling about the economy. Following a a 30% surge from its April lows, the S&P 500 retreated.

Subscribe to the Stock Movers Podcast on Apple, Spotify and other Podcast Platforms.

Treasuries fell across the curve, with longer-dated maturities leading the way. Attention will soon shift to next week’s central bank gathering in Jackson Hole, Wyoming, with traders getting ready for Jerome Powell’s speech.

US retail sales rose in July in a broad-based advance, boosted by car sales and major online promotions. Later, a separate report showed consumer sentiment unexpectedly fell for the first time since April and inflation expectations rose.

“Overall, consumers are no longer bracing for the worst-case scenario for the economy feared in April,” said Peter Boockvar, author of The Boock Report. “However, consumers continue to expect both inflation and unemployment to deteriorate in the future.”

To Bill Adams at Comerica Bank, while the data don’t all point in the same direction, the US economy looks to be in OK shape.

“What consumers do is more important to the economy than what they say,” he said.

Investors also awaited a face-to-face summit between Donald Trump and Vladimir Putin in Alaska due to start at 3 p.m. New York time.

To Bret Kenwell at eToro, July’s retail sales figures weren’t necessarily a blowout. However, control group sales — which are used in the gross domestic product calculation — topped economists’ expectations, while June’s already strong report was revised even higher.

Retailers will start reporting earnings next week, which should provide more insights into consumer behavior, he noted.

As long as consumer spending holds up and companies are able to retain workers because of that robust spending, the flywheel can continue to spin, pushing corporate profits and stock prices higher, according to Chris Zaccarelli at Northlight Asset Management.

US stocks are set to decline in the event of dovish signals from the Federal Reserve at the Jackson Hole economic symposium as investors “buy rumor, sell fact,” according to Bank of America Corp. strategists led by Michael Hartnett.

Money markets still see high odds of a Fed rate cut in September, with at least two reductions by the end of the year.

Investors poured about $21 billion into US equity funds in the week through Aug. 13, after redeeming nearly $28 billion in the week prior, according to the note citing EPFR Global data.

Corporate Highlights:

The Trump administration is considering using funds from the US Chips Act to take a stake in the beleaguered American chipmaker Intel Corp., according to people familiar with the discussions. Applied Materials Inc., the largest American producer of chipmaking gear, gave a disappointing sales and profit forecast, renewing concerns that the US trade dispute with China is weighing on demand. UnitedHealth Group Inc. jumped after funds piled into the company, which has been hampered by a federal probe into its business practices and weakening results. Warren Buffett’s Berkshire Hathaway Inc. was among the investors, buying 5 million shares, according to a filing. David Tepper’s Appaloosa Management LP also invested, boosting its holdings of the health insurance giant by 2.3 million shares. Swiss chocolatier Lindt & Spruengli AG may shift production of its world-famous, gold-wrapped Easter bunnies to the US to sidestep import tariffs. Danish jewelry company Pandora A/S is weighing potential price increases in the US due to higher tariffs, according to its chief executive officer. AstraZeneca Plc released its flu vaccine nasal spray for at-home use on Friday, an option that comes at a contentious time for vaccine access in the US. Some of the moves in markets:

Stocks

The S&P 500 fell 0.3% as of 12 p.m. New York time The Nasdaq 100 fell 0.5% The Dow Jones Industrial Average rose 0.2% The Stoxx Europe 600 was little changed The MSCI World Index was little changed Bloomberg Magnificent 7 Total Return Index fell 0.3% The Russell 2000 Index fell 0.6% Currencies

The Bloomberg Dollar Spot Index fell 0.3% The euro rose 0.5% to $1.1706 The British pound rose 0.2% to $1.3562 The Japanese yen rose 0.5% to 147.01 per dollar Cryptocurrencies

Bitcoin fell 0.5% to $117,352.15 Ether fell 2.3% to $4,431.94 Bonds

The yield on 10-year Treasuries advanced three basis points to 4.32% Germany’s 10-year yield advanced eight basis points to 2.79% Britain’s 10-year yield advanced five basis points to 4.70% The yield on 2-year Treasuries advanced one basis point to 3.75% The yield on 30-year Treasuries advanced four basis points to 4.92% Commodities

West Texas Intermediate crude fell 1.2% to $63.19 a barrel Spot gold rose 0.2% to $3,342.17 an ounce ©2025 Bloomberg L.P.

Microsoft has launched an “urgent” external inquiry into allegations Israel’s military surveillance agency has used the company’s technology to facilitate the mass surveillance of Palestinians.

The company said on Friday the formal review was in response to a Guardian investigation that revealed how the Unit 8200 spy agency has relied on Microsoft’s Azure cloud platform to store a vast collection of everyday Palestinian mobile phone calls.

The joint investigation with the Israeli-Palestinian publication +972 Magazine and the Hebrew-language outlet Local Call found Unit 8200 made use of a customised and segregated area within Azure to store recordings of millions of calls made daily in Gaza and the West Bank.

In a statement, Microsoft said “using Azure for the storage of data files of phone calls obtained through broad or mass surveillance of civilians in Gaza and the West Bank” would be prohibited by its terms of service.

The inquiry, to be overseen by lawyers at the US firm Covington & Burling, is the second external review commissioned by Microsoft into the use of its technology by the Israeli military.

The first was launched this year amid dissent within the company and reports by the Guardian and others about Israel’s reliance on the company’s technology during its offensive in Gaza. Announcing the review’s findings in May, Microsoft said it had “found no evidence to date” the Israeli military had failed to comply with its terms of service or used Azure “to target or harm people” in Gaza.

However, the recent Guardian investigation prompted concerns among senior Microsoft executives about whether some of its Israel-based employees may have concealed information about how Unit 8200 uses Azure when questioned as part of the review.

Microsoft said on Friday the new inquiry would expand on the earlier one, adding: “Microsoft appreciates that the Guardian’s recent report raises additional and precise allegations that merit a full and urgent review.”

The company is also facing pressure from a worker-led campaign group, No Azure for Apartheid, which has accused it of “complicity in genocide and apartheid” and demanded it cut off “all ties to the Israeli military” and make them publicly known.

Since the Guardian and its partners, +972 and Local Call, revealed Unit 8200’s sweeping surveillance project last week, Microsoft has been scrambling to assess what data the unit holds in Azure.

Several Microsoft sources familiar with internal deliberations said the company’s leadership was concerned by information from Unit 8200 sources interviewed for the article, including claims that intelligence drawn from repositories of phone calls held in Azure had been used to research and identify bombing targets in Gaza.

Israel’s 22-month bombardment of the territory, launched after the Hamas-led attack on 7 October 2023, has killed more than 60,000 people, the majority of them civilians, according to the health authority in the territory, though the actual death toll is likely to be significantly higher.

Senior Microsoft executives had in recent days considered an awkward scenario in which Unit 8200, an important and sensitive customer, could be in breach of the company’s terms of service and human rights commitments, sources said.

According to leaked files reviewed by the Guardian, the company was aware as early as late 2021 that Unit 8200 planned to move large volumes of sensitive and classified intelligence data into Azure.

At Microsoft’s headquarters in November that year, senior executives – including its chief executive, Satya Nadella – attended a meeting during which Unit 8200’s commander discussed a plan to move as much as 70% of its data into the cloud platform.

The company has said its executives, including Nadella, were not aware Unit 8200 planned to use or ultimately used Azure to store the content of intercepted Palestinian calls. “We have no information related to the data stored in the customer’s cloud environment,” a spokesperson said last week.

An Israeli military spokesperson has previously said its work with companies such as Microsoft is “conducted based on regulated and legally supervised agreements” and the military “operates in accordance with international law”.

The new inquiry will examine the military’s commercial agreements with Microsoft. Once completed, the company will “share with the public the factual findings that result from this review”, its statement said.

By Steve Goldstein

Bank says allegations are ‘entirely false’

Standard Chartered shares dropped in late London trade.

Standard Chartered PLC shares slumped on Friday after a lawmaker close to the Trump administration requested that the Justice Department probe the bank over alleged sanctions violations.

Rep. Elise Stefanik, in a letter she released to the public, wrote to Attorney General Pam Bondi alleging sanctions evasion by the U.K.-headquartered bank.

Standard Chartered was fined $1.1 billion in 2019 by U.S. and U.K. authorities over evading sanctions and lacking proper money-laundering controls. It’s also facing a $1.9 billion lawsuit in the U.K. by investors over Iran sanctions violations.

The New York Republican said an existing deferred-prosecution agreement is due to expire on Aug. 19.

Standard Chartered shares (UK:STAN) fell in London as the letter was released, losing 7% in late trade.

“The underlying allegations – including the claim that there are $9.6 billion in unlawful transactions – are entirely false and have been rejected by the U.S. courts multiple times,” the bank said in a statement.

The bank said it will “fully cooperate” with any relevant authority.

Stefanik also alleged that New York Attorney General Letitia James – whose agency oversees most foreign banks operating in the U.S. with a New York office – did not take action on the allegations when briefed last year.

Stefanik requested that the acting U.S. attorney for New Jersey, Alina Habba, be in charge of an investigation.

-Steve Goldstein

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

  (END) Dow Jones Newswires

  08-15-25 1147ET
Copyright (c) 2025 Dow Jones & Company, Inc.

Treatment with the combination of bortezomib (Velcade), mitoxantrone hydrochloride liposome (Lipo‐MIT), and dexamethasone (VMitD) led to responses and displayed a manageable safety profile in patients with relapsed/refractory multiple myeloma, according to data from a phase 1 trial (NCT05052970).

Findings published in Cancer Medicine demonstrated that evaluable patients (n = 15) experienced an overall response rate (ORR) of 86.7%, which comprised complete response (CR) or stringent CR (sCR; n = 3); very good partial response (VGPR; n = 6); PR (n = 4); and minor remission (n = 1). One patient experienced stable disease. The 12-month duration of response (DOR) rate was 66.0% (95% CI, 23.92%-88.63%).

Regarding safety, hematologic and non‐hematologic adverse effects (AEs) were common, but the vast majority were mild to moderate. Treatment‐related AEs (TRAEs) did not lead to deaths in any patients. The only common grade 3/4 non-hematologic AE was infectious pneumonia, which occurred in 20% of patients (n = 20). Common grade 3/4 hematologic AEs included thrombocytopenia (70%), neutropenia (55%), lymphopenia (30%), and anemia (10%).

“This trial is the first to present outcomes using a triplet regimen including Lipo‐MIT for relapsed/refractory multiple myeloma, demonstrating good tolerance and promising efficacy,” lead study author Ya‐Lan Zhou, MD, of Department of Hematology at Beijing Chaoyang Hospital of Capital Medical University in China, and colleagues wrote in the publication. “However, further studies are required to more accurately assess patient outcomes, and in‐depth mechanistic studies are needed to identify potential biomarkers that could predict response to this regimen.”

Why Was Lipo‐MIT Evaluated for Relapsed/Refractory Multiple Myeloma?

In China, Lipo-MIT is currently approved for the treatment of patients with relapsed/refractory peripheral T‐cell lymphoma. Given the superior efficacy displayed by Lipo-MIT compared with conventional anthracyclines, investigators sought to evaluate the use of this agent as part of a combination regimen for patients with relapsed/refractory multiple myeloma.

The multicenter, open‐label, phase 1 study enrolled patients at least 18 years of age with relapsed/refractory multiple myeloma who had measurable disease and received at least 1 prior line of treatment. Prior treatment with bortezomib was permitted if patients were not resistant or intolerant to the agent.

Investigators excluded patients with compromised hematologic reserve, liver dysfunction, or diminished performance status. Those in need of hemodialysis were also excluded. Other key exclusion criteria included a history of plasma cell leukemia, HIV, or active hepatitis.

Patients were randomly assigned 1:1:1 to receive varying doses of Lipo-MIT as part of the VMitD regimen. LipoMIT was dosed at 12 mg/m² on day 1 of each 4-week cycle in cohort A, 16 mg/m² in cohort B, and 20 mg/m² in cohort C. In all 3 cohorts, patients received bortezomib at 1.3 mg/m² on days 1, 4, 8, and 11 of each cycle plus dexamethasone at 20 mg on days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle. Eight cycles of treatment were planned for each cohort.

The incidence of treatment-emergent AEs served as the trial’s primary end point. Secondary end points comprised ORR, DOR, clinical benefit rate, disease control rate, progression-free survival (PFS), and overall survival.

Among the overall population (n = 20), the median age was 61.5 years (range, 42-70), and most patients were male (60%), had IgG myeloma (55.0%), and did not have extramedullary plasmacytomas (80%). Patients received a median of 2.5 prior lines of therapy (range, 1-8), and patients had either relapsed (90%) or refractory (10%) disease.

Additional Efficacy and Safety Data

At a median follow‐up of 12.1 months, patients achieved a median OS that was not reached; the estimated 12‐month OS rate was 78.2% (95% CI, 51.36%-91.32%). The 12-month PFS rate was 58.2% (95% CI, 26.94%-79.98%).

In patients with extramedullary plasmacytoma (n = 4), 3 underwent at least one efficacy evaluation. One patient achieved an sCR, and 2 had a VGPR. Disease progression led to death in 1 patient in this subgroup prior to their first evaluation.

Any-grade TRAEs occurred in 85.0% of patients. Other common grade 3 or higher TRAEs included hypokalemia (10.0%), hyponatremia (5.0%), headache (5.0%), and diarrhea (5.0%).

Reference

Zhou YL, Zhang JQ, Wang W, et al. Bortezomib, mitoxantrone hydrochloride liposome, and dexamethasone for relapsed/refractory multiple myeloma: a multi-center, open-label phase I trial. Cancer Med. 2025;14(8):e70890. doi:10.1002/cam4.70890

Nemvaleukin alfa monotherapy demonstrated modest antitumor activity and durable disease control in patients with advanced melanoma or renal cell carcinoma (RCC), according to findings from the phase 1/2 non-randomized ARTISTRY-1 trial (NCT02799095).

Findings published in the Journal for Immunotherapy of Cancer showed that from July 2016 to March 2023, 74 patients enrolled in part B of the study received nemvaleukin alfa monotherapy (melanoma, n = 47; RCC, n = 27). In the melanoma cohort, the objective response rate (ORR) was 9% (95% CI, 2%-21%), and the disease control rate (DCR) was 50% (95% CI, 35%-65%). Stable disease persisted for at least 6 months in 7% of patients.

In the RCC cohort, the ORR was 14% (95% CI, 3%-35%), and the DCR was 50% (95% CI, 28%-72%); 9% of patients achieved stable disease for longer than 6 months.

The most common grade 3/4 nemvaleukin alfa–related treatment-emergent adverse effect (TEAE) was neutropenia, reported in 57% of patients with melanoma and 33% of patients with RCC. No patients in either cohort experienced grade 3 or higher cytokine release syndrome (CRS) or infusion-related reactions, and there were no reported cases of capillary leak syndrome or febrile neutropenia.

“Nemvaleukin [alfa] demonstrated pharmacodynamic proof of mechanism, with single-agent antitumor activity and manageable safety in patients with advanced melanoma and RCC,” lead study author Emiliano Calvo, MD, PhD, director of Clinical Research at START Madrid-CIOCC and START Madrid-FJD in Spain, and colleagues wrote in the publication of the data.

ARTISTRY-1 Trial Breakdown

The phase 1/2 ARTISTRY-1 trial was a global, multicenter, open-label study conducted across 32 sites in 7 countries. The trial comprised three parts: part A (dose-escalation monotherapy), part B (dose-expansion monotherapy), and part C (nemvaleukin alfa in combination with pembrolizumab [Keytruda]).

Eligible patients for part B were at least 18 years of age, had an ECOG performance status of 0 or 1, and had at least one measurable target lesion per RECIST 1.1 criteria.

The melanoma cohort included patients who had received prior immune checkpoint inhibitor (ICI) therapy with or without anti–CTLA-4 therapy, and, when appropriate, molecularly targeted therapy. Patients could have received no more than one prior cytotoxic chemotherapy regimen. In the RCC cohort, enrollment was permitted regardless of prior ICI exposure, provided patients with prior anti–PD-(L)1 treatment had received no more than 2 prior systemic regimens, including the ICI-containing regimen.

Patients were required to have achieved at least stable disease or better with prior ICI therapy unless approved for enrollment on a case-by-case basis by the medical monitor. Key exclusion criteria included active autoimmune disease requiring systemic therapy within 3 months, history of severe autoimmune disease necessitating systemic immunosuppression, or prior IL-2– or IL-15–based therapy.

In part B, nemvaleukin alfa was administered at the recommended phase 2 dose of 6 µg/kg once daily on days 1-5 of each cycle. Cycle 1 lasted 14 days, with 9 days off treatment; subsequent cycles were 21 days, with 16 days off treatment.

Primary objectives for part B were ORR per RECIST 1.1 criteria and to characterize the safety profile, including incidence and severity of TEAEs. Secondary objectives included evaluating pharmacokinetics, antidrug antibody incidence, DCR, duration of response, progression-free survival, and changes in peripheral immune cell subsets, including CD8-positive T cells, regulatory T cells, and natural killer cells.

Patient Demographics

In part B of the ARTISTRY-1 trial, the median age was 66 years (range, 37-82) for patients in the melanoma cohort and 69 years (range, 39-77) for those in the RCC cohort. Males comprised 53% of the melanoma cohort and 89% of the RCC cohort. Most patients were White (melanoma, 89%; RCC, 93%), with smaller proportions identifying as Asian (11%; 4%) or Black/African American (0%; 4%).

Performance status was evenly distributed in the melanoma group, with 49% having an ECOG performance status of 0 and 51% having a score of 1. In contrast, the RCC cohort, 26% had an ECOG performance status of 0, and 74% had a score of 1. Patients were heavily pretreated, with a median of 3 prior lines of therapy (range, 1-8) in the melanoma cohort and 2 (range, 1-8) in the RCC cohort.

Prior ICI exposure was common, with anti–PD-1 therapy received by 96% of patients with melanoma and 56% of patients with RCC; prior anti–PD-L1 therapy was given to 6% and 7% of patients, respectively; anti–CTLA-4 therapy was received by 36% and 15%, respectively; and combination anti–PD-1 plus anti–CTLA-4 therapy was administered to 6% and 4%, respectively.

Among the melanoma cohort, 40% had baseline lactate dehydrogenase (LDH) levels above normal, with a median of 438 U/L (range, 233-1921 U/L); 60% had levels within normal limits. In the RCC cohort, 74% had clear cell histology, with the remainder having variants including clear cell and oncocytoma (n = 1), clear cell and non–clear cell (n = 1), and clear cell with rhabdoid features (n = 1).

Safety and Pharmacokinetic/Pharmacodynamic Findings

In part B, patients with advanced melanoma or RCC received a median of six treatment cycles, corresponding to a median treatment duration of 14.7 weeks in both cohorts. Relative dose intensity was high, with a median of 98% in each group. Rates of dose interruptions and dose reductions were similar between cohorts.

Nearly all patients experienced at least one nemvaleukin alfa–related treatment-related AE (TRAE), with incidences of 96% in the melanoma cohort and 100% in the RCC cohort. Grade 3 or 4 TRAEs occurred in 77% and 74% of patients, respectively. In the melanoma group, the most common TRAEs of any grade reported in at least 25% of patients included fever (68%), nausea (47%), and neutropenia (47%), whereas in RCC, these were fever (59%), chills (52%), and neutropenia (41%). Neutropenia was the most frequent grade 3/4 TRAE, reported in 57% of patients with melanoma and 33% of patients with RCC.

Nemvaleukin alfa–related serious AEs were observed in 15% of patients with melanoma and 30% of patients with RCC. Infusion-related reactions occurred in 2% and 15% of patients, respectively, while CRS was reported in 2% of patients with melanoma. Filgrastim was used in 5% of patients for neutropenia management.

TRAEs leading to treatment discontinuation were uncommon (4% in melanoma; 4% in RCC). One death due to COVID-19 occurred in the RCC cohort and was deemed unrelated to treatment.

Pharmacokinetic analyses demonstrated similar nemvaleukin alfa exposure between cohorts. Following the first intravenous infusion at 6 µg/kg, peak serum concentrations were reached at approximately 0.5 hours post infusion—106 ng/mL in melanoma and 132 ng/mL in RCC—and declined slowly in a monophasic pattern, remaining detectable at 24 hours post-dose. Trough concentrations decreased from cycle 1, day 2 to cycle 1, day 5, with stabilization during cycle 2, suggesting achievement of steady state by cycle 2, day 2. Area under the concentration-time curves and time to last quantifiable concentration were comparable across cohorts.

“Overall, nemvaleukin [alfa] demonstrated preliminary antitumor activity in patients with advanced melanoma and RCC, along with a manageable safety profile, and selective activation of the proinflammatory immune pathways, supporting its potential as an active and tolerable cytokine therapy,” said Calvo. “Future research should focus on identifying optimal patient subsets, tumor types, and combination strategies to maximize the therapeutic benefit.”

Reference

Calvo E, Boni V, Dumas O, et al. Nemvaleukin alfa monotherapy in patients with advanced melanoma and renal cell carcinoma: results from the phase 1/2 non-randomized ARTISTRY-1 trial. J Immunother Cancer. 2025;13(8):e010777. doi:10.1136/jitc-2024-010777

TLDRs:

• OpenAI pivots to enterprise with GPT-5, providing faster setup and cost-effective AI for startups.
• Box, Vercel, and Factory adopt GPT-5, citing improved coding and complex task management.
• GPT-5 pricing undercuts competitors, aiming to capture market share from Anthropic’s Claude models.
• Enterprise adoption drives AI market growth, with OpenAI expanding sales teams globally.

OpenAI is accelerating its enterprise strategy with the rollout of GPT-5, targeting startups and established businesses seeking faster, more affordable AI solutions.

While the model faced initial criticism, OpenAI reinstated GPT-4 access for paid subscribers, highlighting its commitment to user flexibility.

Startups such as Cursor, Vercel, and Factory have already integrated GPT-5 as the default model for coding and planning tasks, citing its faster setup and lower operational costs. Box, a leading cloud content management firm, reported notable improvements in document analysis and complex workflow handling using GPT-5. Other tech companies, including Qodo and JetBrains, echoed similar praise for the model’s capabilities.

Faster, Smarter, Cheaper

The visual impact of GPT-5 adoption extends beyond efficiency gains. Startups leveraging the model are able to streamline operations and accelerate development timelines.

OpenAI has made GPT-5 accessible through both Microsoft Azure and its proprietary API, ensuring enterprises can integrate AI tools with existing infrastructure.

This dual-access strategy positions OpenAI as a flexible partner for businesses of all sizes, from startups to large enterprises.

Startups Lead GPT-5 Adoption

The shift toward enterprise represents a strategic departure from OpenAI’s historically consumer-focused approach.

Currently, ChatGPT Plus subscriptions account for 80% of OpenAI’s revenue, in contrast to competitors like Anthropic, which derive most of their earnings from enterprise API usage. Analysts suggest that focusing on enterprise adoption offers more sustainable revenue streams and broader growth potential.

Market projections reinforce this trend. The generative AI sector is expected to expand from $10.9 billion in 2023 to $42.6 billion by 2028, with enterprise clients driving much of this growth. OpenAI’s pricing strategy for GPT-5—significantly cheaper than Anthropic’s Claude models, indicates a deliberate move to capture enterprise market share even at the cost of short-term margins.

Market Moves and Strategy

Enterprise clients represent both an opportunity and a risk for AI providers. Anthropic’s revenue, heavily concentrated among just two major customers, illustrates the vulnerability of relying on a narrow client base.

GPT-5’s competitive pricing offers enterprises a cost-efficient alternative, creating a potential shift in the AI-powered coding market.

Historically, losing a single large client in enterprise software can drastically impact growth, highlighting OpenAI’s advantage in diversifying its customer base early.

OpenAI Expands Access Globally

OpenAI’s expanded enterprise sales team, combined with aggressive market positioning, signals a decisive push into the business segment.

As startups and established companies increasingly adopt GPT-5 for coding, planning, and complex task management, the AI landscape is poised for a new phase of competition and innovation.

With GPT-5, OpenAI aims to balance cutting-edge AI performance with affordability, ensuring enterprises gain both speed and cost efficiency. The model’s uptake among startups and tech companies demonstrates its growing influence, potentially reshaping how businesses deploy AI in the coming years.

Amazon founder Jeff Bezos’ mother, Jacklyn Gise Bezos, has died following a battle with Lewy body dementia, he announced on Instagram. She was 78.

Gise Bezos died in her Miami home on Thursday, according to the Bezos Scholars Program, a foundation she started with her husband, Mike Bezos.

“After a long fight with Lewy Body Dementia, she passed away today, surrounded by so many of us who loved her — her kids, grandkids, and my dad,” Bezos, her eldest son, wrote in an Instagram post on Thursday. “I know she felt our love in those final moments.”